文献速递糖尿病肥胖与代谢综合征

脂蛋白(a)与冠心病合并糖尿病前期或糖尿病患者的心血管结局

Lipoprotein(a) and Cardiovascular Outcomes in Patients With Coronary Artery Disease and Prediabetes or Diabetes.
PubMed 文献 · Diabetes Care · 2019-05-10

该多中心队列连续纳入5143例稳定冠心病患者,按糖代谢状态分组并依脂蛋白(a)水平细分,中位随访6.1年。结果显示脂蛋白(a)升高与糖尿病前期及糖尿病患者心血管事件风险增加相关,而在糖代谢正常者中预测价值不显著。

要点

  • 糖尿病前期和糖尿病患者中脂蛋白(a)升高与心血管事件风险增加相关
  • 脂蛋白(a)加入Cox模型可小幅提升糖尿病前期和糖尿病患者的预测能力
  • 糖代谢正常者中脂蛋白(a)对心血管事件预测无统计学改善

核心结论

  • 脂蛋白(a)升高可能影响糖尿病前期合并稳定冠心病患者的预后,有助于进一步危险分层。

研究设计与样本

  • 多中心研究,2011年3月至2015年2月连续纳入5143例稳定冠心病患者。
  • 按糖代谢状态分为糖尿病、糖尿病前期和糖代谢正常三组,并依脂蛋白(a)水平进一步分为12组。
  • 中位随访6.1年,终点为非致死性急性心肌梗死、卒中和心血管死亡。

主要发现

  • 随访期间共发生435例(8.5%)心血管事件。
  • 糖代谢正常组与糖尿病前期组心血管事件发生率无显著差异(HR 1.131,95%CI 0.822-1.556,P>0.05)。
  • 糖尿病前期组中,脂蛋白(a) 30-<50 mg/dL和≥50 mg/dL与心血管事件风险升高相关(HR分别为2.181[95%CI 1.099-4.327]和2.668[95%CI 1.383-5.415],均P<0.05)。
  • 糖尿病组中,脂蛋白(a) 30-<50 mg/dL和≥50 mg/dL与心血管事件风险升高相关(HR分别为3.088[95%CI 1.535-5.895]和3.470[95%CI 1.801-6.686],均P<0.05)。
  • 将脂蛋白(a)加入Cox模型后,糖尿病前期组和糖尿病组的C统计量分别提高0.022和0.029,而糖代谢正常组无统计学改善。

临床怎么用

  • 对稳定冠心病合并糖尿病前期或糖尿病患者,可考虑检测脂蛋白(a)以辅助危险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of the current study is to determine the impact of elevated lipoprotein(a) [Lp(a)] on cardiovascular events (CVEs) in stable coronary artery disease (CAD) patients with different glucose metabolism status. RESEARCH DESIGN AND METHODS: In this multicenter study, we consecutively enrolled 5,143 patients from March 2011 to February 2015. Patients were categorized according to status of glucose metabolism (diabetes mellitus [DM], pre-diabetes mellitus [pre-DM], and normal glucose regulation [NGR]) levels and further classified into 12 groups by Lp(a) levels. CVE end points included nonfatal acute myocardial infarction (MI), stroke, and cardiovascular mortality. All subjects were followed up for the occurrence of the CVEs. RESULTS: During a median of 6.1 years' follow-up, 435 (8.5%) CVEs occurred. No significant difference in occurrence of CVEs was observed between NGR and pre-DM groups (hazard ratio 1.131 [95% CI 0.822-1.556], P > 0.05). When status of glucose metabolism was incorporated in stratifying factors, 30 ≤ Lp(a) < 50 mg/dL and Lp(a) ≥50 mg/dL were associated with significantly higher risk of subsequent CVEs in pre-DM (2.181 [1.099-4.327] and 2.668 [1.383-5.415], respectively; all P < 0.05) and DM (3.088 [1.535-5.895] and 3.470 [1.801-6.686], all P < 0.05). Moreover, adding Lp(a) to the Cox model increased the C-statistic by 0.022 and 0.029 in pre-DM and DM, respectively, while the C-statistic was not statistically improved when Lp(a) was included for CVEs prediction in NGR. CONCLUSIONS: Our findings, for the first time, indicated that elevated Lp(a) levels might affect the prognosis in patients with pre-DM with stable CAD, suggesting that Lp(a) may help further stratify stable CAD patients with mild impaired glucose metabolism.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Jin JL, Cao YX, Zhang HW, et al. Lipoprotein(a) and Cardiovascular Outcomes in Patients With Coronary Artery Disease and Prediabetes or Diabetes. Diabetes Care. 2019. PMID: 31076417. doi:10.2337/dc19-0274

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。